Comparative Rx Economic Claims Without Head-to-Head Trials Risky – J&J’s Jimenez
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson Associate General Counsel Freddy Jimenez acknowledges a continued reluctance among biopharmaceutical companies to make health care economic claims in the absence of further guidance from FDA.
You may also be interested in...
FDA's Off-Label Communication Changes Should Start With Payers – PhRMA
PhRMA Senior Counsel Jeffrey Francer offers three-step reform approach to loosening FDA’s restrictions, beginning with the 'low-hanging fruit' of talking with payers.
FDA Guidance On Health Care Economic Data Is Coming In 2015
Agency originally said it would issue a draft guidance on industry’s interactions with formulary committees in 2014, but CDER Director Woodcock says “extremely contentious” issues have slowed progress.
FDA Promises More Off-label Guidances As Part Of First Amendment Harmonization
Agency grants two citizen petitions from a coalition of pharma companies requesting greater clarity from FDA, but whether the forthcoming guidances will satisfy industry remains an open question.